The platinum analog CI-973 was selected for clinical study because it is associated with fewer and milder toxicities than either cisplatin or carboplatin in experimental animals, and because it has activity against cisplatin-resistant cell lines in vitro. In this Phase 2 study, 31 women with platinum-resistant or recurrent ovarian carcinoma were treated with CI-973. Three patients achieved a complete response, defined as the disappearance of all measurable disease. The median Kaplan-Meier survival time was estimated to be approximately 7 months from the start of treatment. The most frequently occurring drug-related toxicities were neutropenia, nausea, vomiting, asthenia, anemia, abdominal pain, and diarrhea. Most toxicities were mild or moderate and none resulted in withdrawal from treatment. Despite this favorable toxicity profile, the low response rate of 10% does not support further clinical development of CI-973 as treatment for ovarian cancer.
- ovarian cancer
- Phase 2 study
- platinum analog
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.